Duracyte’s implants employ cells engineered to produce therapeutic protein, bypassing the complexities of traditional biologics manufacturing. The startup’s marriage of biotechnology with electronics comes with on-board sensors that enable clinicians to monitor and control an implant’s drug production process.

RBL LLC has launched Duracyte, a revolutionary biotech company creating implantable devices to continuously produce therapeutic proteins in patients' bodies.

Duracyte is a biotechnology company developing implantable "living pharmacy" devices designed to continuously produce therapeutic proteins inside the body The company plans to initiate a Phase 1 clinical trial this year evaluating patients with recurrent ovarian cancer Duracyte is the...